Extracts of the medicinal herb Sanguisorba officinalis inhibit the entry of human immunodeficiency virus-1

Journal of Food and Drug Analysis

Volumn 21, Issue 4 SUPPL., 2013, Pages

  Liang, Jianguo ^a   Chen, Jianping ^b,c   Tan, Zhiwu ^a   Peng, Jie ^a   Zheng, Xiao ^b   Nishiura, Kenji ^a   Ng, Jenny ^a   Wang, Zhiyu ^b   Wang, Dongmei ^c   Chen, Zhiwei ^a   Liu, Li ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b THE UNIVERSITY OF HONG KONG   (Hong Kong)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

Entry inhibitor; Highly active antiretroviral therapy; Human immunodeficiency virus; Sanguisorba officinalis; Traditional Chinese medicine

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; ENFUVIRTIDE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; JM 2987; MARAVIROC; NEVIRAPINE; PLANT EXTRACT; RNA DIRECTED DNA POLYMERASE INHIBITOR; SANGUISORBA OFFICINALIS EXTRACT; SOLVENT; UNCLASSIFIED DRUG; VIRUS RECEPTOR;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; CELL ASSAY; CELL LINE; CONFERENCE PAPER; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; INFLUENZA VIRUS A H5N1; NONHUMAN; SANGUISORBA; SANGUISORBA OFFICINALIS; SARS CORONAVIRUS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SOLVENT EXTRACTION; VESICULAR STOMATITIS VIRUS; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TYPING;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; SANGUISORBA OFFICINALIS; SARS CORONAVIRUS; VESICULAR STOMATITIS VIRUS;

EID: 84897028332     PISSN: 10219498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jfda.2013.09.034     Document Type: Conference Paper

References (33)

1. White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother 1997;41:1413-22.
2. Zou W, Liu Y, Wang J, et al. Traditional Chinese herbal medicines for treating HIV infections and AIDS. Evid Based Complement Alternat Med 2012;2012:950757.
3. Liu JP. The use of herbal medicines in early drug development for the treatment of HIV infections and AIDS. Expert Opin Investig Drugs 2007;16:1355-64.
4. Cui M, Li J, Li H, et al. Herbal compatibility of traditional Chinese medical formulas for acquired immunodeficiency syndrome. J Tradit Chinese Med 2012;32:329-34.
5. Man S, Gao W, Wei C, et al. Anticancer drugs from traditional toxic Chinese medicines. Phytother Res 2012;26:1449-65.
6. Wang J, Zou W. Practices, challenges, and opportunities: HIV/AIDS treatment with traditional Chinese medicine in China. Front Med 2011;5:123-6.
7. Chu Y, Liu H. Advances of research on anti-HIV agents from traditional Chinese herbs. Adv Dent Res 2011;23:67-75.
8. Lu X, Liu L, Zhang X, et al. F18, a novel small-molecule nonnucleoside reverse transcriptase inhibitor, inhibits HIV-1 replication using distinct binding motifs as demonstrated by resistance selection and docking analysis. Antimicrob Agents Chemother 2012;56:341-51.
9. Ma T, Liu L, Xue H, et al. Chemical library and structureactivity relationships of 11-demethyl-12-oxo calanolide A analogues as anti-HIV-1 agents. J Med Chem 2008;51:1432-46.
10. Wang J, Zou W. Recent advances of HIV/AIDS treatment with traditional Chinese medicine in China. J Tradit Chinese Med 2010;30:305-8.
11. Zhang S, Liu X, Zhang ZL, et al. Isolation and identification of the phenolic compounds fromthe roots of Sanguisorba officinalis L. and their antioxidant activities.Molecules 2012;17:13917-22.
12. Goun EA, Petrichenko VM, Solodnikov SU, et al. Anticancer and antithrombin activity of Russian plants. J Ethnopharmacol 2002;81:337-42.
13. Zberts VL, Plakhova NB. Application of burnet (Sanguisorba officinalis) in treatment of dysentery in children. Sovetskaia Meditsina 1951;4:27-9 [Article in Russian].
14. Wang Z, Loo WT, Wang N, et al. Effect of Sanguisorba officinalis L on breast cancer growth and angiogenesis. Expert Opin Ther Targets 2012;16(Suppl. 1):S79-89.
15. Liu L, Fang Q, Deng F, et al. Natural mutations in the receptor binding domain of spike glycoprotein determine the reactivity of cross-neutralization between palm civet coronavirus and severe acute respiratory syndrome coronavirus. J Virol 2007;81:4694-700.
16. Sun C, Chen Z, Tang X, et al. Mucosal priming with a replicating-vaccinia virus-based vaccine elicits protective immunity to simian immunodeficiency virus challenge in rhesus monkeys. J Virol 2013;87:5669-77.
17. Chen MW, Cheng TJ, Huang Y, et al. A consensushemagglutinin- based DNA vaccine that protects mice against divergent H5N1 influenza viruses. Proc Natl Acad Sci U S A 2008;105:13538-43.
18. Rapista A, Ding J, Benito B, et al. Human defensins 5 and 6 enhance HIV-1 infectivity through promoting HIV attachment. Retrovirology 2011;8:45.
19. Gustchina E, Hummer G, Bewley CA, et al. Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV. J Med Chem 2005;48:3036-44.
20. Kang Y, Wu Z, Lau TC, et al. CCR5 antagonist TD-0680 uses a novel mechanism for enhanced potency against HIV-1 entry, cell-mediated infection, and a resistant variant. J Biol Chem 2012;287:16499-509.
21. Kang Y, Guo J, Chen Z. Closing the door to human immunodeficiency virus. Protein Cell 2013;4:86-102.
22. Biswas P, Tambussi G, Lazzarin A. Access denied? The status of co-receptor inhibition to counter HIV entry. Expert Opin Pharmacother 2007;8:923-33.
23. Chen Z, Telfer P, Reed P, et al. Isolation and characterization of the first simian immunodeficiency virus from a feral sooty mangabey (Cercocebus atys) in West Africa. J Med Primatol 1995;24:108-15.
24. Chen Z, Zhou P, Ho DD, et al. Genetically divergent strains of simian immunodeficiency virus use CCR5 as a coreceptor for entry. J Virol 1997;71:2705-14.
25. Zhang L, He T, Huang Y, et al. Chemokine coreceptor usage by diverse primary isolates of human immunodeficiency virus type 1. J Virol 1998;72:9307-12.
26. Moriuchi M, Moriuchi H, Turner W, et al. Cloning and analysis of the promoter region of CXCR4, a coreceptor for HIV-1 entry. J Immunol 1997;159:4322-9.
27. Samson M, Labbe O, Mollereau C, et al. Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry 1996;35:3362-7.
28. Chen Z, Telfier P, Gettie A, et al. Genetic characterization of new West African simian immunodeficiency virus SIVsm: Geographic clustering of household-derived SIV strains with human immunodeficiency virus type 2 subtypes and genetically diverse viruses from a single feral sooty mangabey troop. J Virol 1996;70:3617-27.
29. Liu S, Lu H, Zhao Q, et al. Theaflavin derivatives in black tea and catechin derivatives in green tea inhibit HIV-1 entry by targeting gp41. Biochim Biophys Acta 2005;1723:270-81.
30. Perelson AS, Ribeiro RM. Estimating drug efficacy and viral dynamic parameters: HIV and HCV. Stat Med 2008;27:4647-57.
31. Han H, He W, Wang W, et al. Inhibitory effect of aqueous Dandelion extract on HIV-1 replication and reverse transcriptase activity. BMC Complement Altern Med 2011;11:112.
32. Park IW, Han C, Song X, et al. Inhibition of HIV-1 entry by extracts derived from traditional Chinese medicinal herbal plants. BMC Complement Altern Med 2009;9:29.
33. Au TK, Lam TL, Ng TB, et al. A comparison of HIV-1 integrase inhibition by aqueous and methanol extracts of Chinese medicinal herbs. Life Sci 2001;68:1687-94.